: Identified by Barclays as a value play for 2026 due to its solid pipeline and high dividend yield, despite near-term patent expirations.
: Featured as a top pick for its ability to overcome patent cliffs through successors like Skyrizi and Rinvoq, maintaining its status as a Dividend King .
: Recognized as a "no-brainer" for 2026 by Yahoo Finance analysts , driven by its lead in the obesity market with tirzepatide (Zepbound and Mounjaro) and a robust oncology pipeline.
: Listed as one of the best pharmaceutical dividend stocks for 2026, showing steady clinical progress and outperforming the broader market.
